| Mclean Hospital Corporation | |
| 115 Mill Street, Belmont, Massachusetts 02478 | |
| (617) 855-3450 | |
| Not Available |
| Name | Mclean Hospital Corporation |
|---|---|
| Type | Psychiatric Hospital |
| Location | 115 Mill Street, Belmont, Massachusetts |
| Ownership | Voluntary non-profit - Private |
| Emergency Services | No |
| Medicare ID (CCN) | 224007 |
| NPI Number | 1538185475 |
| Organization Name | THE MCLEAN HOSPITAL CORPORATION |
| Address | 115 Mill St, Belmont, MA 02478 |
| Hospital Type | Psychiatric Hospital |
| Phone Number | 617-855-3316 |
News Archive
Flavoring can change how the brain responds to e-cigarette aerosols that contain nicotine, according to Penn State College of Medicine researchers.
InterMune, Inc. today announced that the company's Marketing Authorization Application (MAA), submitted on March 2 seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, was validated by the European Medicines Agency (EMA). Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24. The proposed trade name for pirfenidone in both the United States and Europe is Esbriet®.
Walking with a wearable robotic exoskeleton may enable people with multiple sclerosis to walk more efficiently by reducing the energy and muscle activity needed to walk, according to research presented this week at the Association for Academic Physiatrists Annual Meeting in Sacramento, Calif.
Researchers have shown for the first time that it is possible to detect signs of urothelial cancer using a simple, postal, urine test in Lynch Syndrome (LS) patients who are at high risk of developing tumors.
› Verified 7 days ago
News Archive
Flavoring can change how the brain responds to e-cigarette aerosols that contain nicotine, according to Penn State College of Medicine researchers.
InterMune, Inc. today announced that the company's Marketing Authorization Application (MAA), submitted on March 2 seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, was validated by the European Medicines Agency (EMA). Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24. The proposed trade name for pirfenidone in both the United States and Europe is Esbriet®.
Walking with a wearable robotic exoskeleton may enable people with multiple sclerosis to walk more efficiently by reducing the energy and muscle activity needed to walk, according to research presented this week at the Association for Academic Physiatrists Annual Meeting in Sacramento, Calif.
Researchers have shown for the first time that it is possible to detect signs of urothelial cancer using a simple, postal, urine test in Lynch Syndrome (LS) patients who are at high risk of developing tumors.
› Verified 7 days ago
Mclean Hospital Corporation Psychiatric Hospital Location: 115 Mill Street, Belmont, Massachusetts 02478 Phone: (617) 855-3450 |